Tezel Lab
![Tazel lab members working with Dr. Tazel in a lab](https://www.vagelos.columbia.edu/sites/default/files/styles/cola_media_200_16_9/public/media/images/2022-08/tazel-lab.jpg?itok=UFf3hA1B 200w, https://www.vagelos.columbia.edu/sites/default/files/styles/cola_media_260_16_9/public/media/images/2022-08/tazel-lab.jpg?itok=kocposy5 260w, https://www.vagelos.columbia.edu/sites/default/files/styles/cola_media_320_16_9/public/media/images/2022-08/tazel-lab.jpg?itok=lO3Vadz0 320w, https://www.vagelos.columbia.edu/sites/default/files/styles/cola_media_400_16_9/public/media/images/2022-08/tazel-lab.jpg?itok=Ec62NgRB 400w, https://www.vagelos.columbia.edu/sites/default/files/styles/cola_media_520_16_9/public/media/images/2022-08/tazel-lab.jpg?itok=Xe13JzBS 520w, https://www.vagelos.columbia.edu/sites/default/files/styles/cola_media_640_16_9/public/media/images/2022-08/tazel-lab.jpg?itok=vCnyurvu 640w, https://www.vagelos.columbia.edu/sites/default/files/styles/cola_media_800_16_9/public/media/images/2022-08/tazel-lab.jpg?itok=oKSkPCoX 800w, https://www.vagelos.columbia.edu/sites/default/files/styles/cola_media_1040_16_9/public/media/images/2022-08/tazel-lab.jpg?itok=bK8zg5un 1040w, https://www.vagelos.columbia.edu/sites/default/files/styles/cola_media_1280_16_9/public/media/images/2022-08/tazel-lab.jpg?itok=HRb3L3pf 1280w, https://www.vagelos.columbia.edu/sites/default/files/styles/cola_media_1600_16_9/public/media/images/2022-08/tazel-lab.jpg?itok=YmgNWzDO 1600w)
Location and Contact Information
701 W. 168th Street
Hammer Health Sciences Building, 2nd floor
New York, NY 10032
United States- Phone 212-342-3841
- Phone 212-342-3816
Principal Investigator
Glaucoma, a multifactorial neurodegenerative disease, is a leading cause of blindness, with no curative treatment currently available. Tezel Lab evaluates the big picture of this complex disease that encompasses multiple stressors, multiple injury sites, multiple cell types, and multiple signaling pathways for asynchronous degeneration of RGCs during a chronic disease period. The longstanding interest of Tezel Lab in the cellular and molecular mechanisms, new treatment targets, and biomarkers of glaucoma motivates parallel studies that complement each other to better understand glaucomatous neurodegeneration and to provide a translational path toward new strategies for testing and treating glaucoma patients.